← Leaderboards
Andrew David White
University Of Michigan At Ann Arbor
$662,877
Attributed
$1,325,753
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $459.7K · FY2019–21$500K$375K$250K$125K$0
'19
'20
'21
Funding mix
By agency
NIH$1,325,753 · 1
By mechanism
R33$1,325,753 · 1
Top collaborators
- Vernon Bruce Carruthers3 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Mary O'Riordan$7,626,725
- Gabriel Nunez$34,455,724
- Peter K Todd$13,268,977
- Victor J. Dirita$11,144,772
- Christiane Wobus$7,155,858
Others in their field
Other Emerging Leaders on “Cytoplasm”
- Kristen Leann Gullo · Us Worldmeds, Llc$6,476,657
- Yamuna Krishnan · University Of Chicago$5,740,000
- Kevin L. Gardner · Columbia University Health Sciences$5,645,546
- David M Glover · California Institute Of Technology$5,639,914
- Jeongmin Song · Cornell University$5,599,559
- Tanya Christineh Petrossian · Endomet Biosciences, Inc$5,081,996
Research focus
CytoplasmAcute InfectionAmericanCystAttenuatedBaseBiochemistryBlindnessAnalogAbcb1 GeneBrainBrain DiseasesCarboxypeptidase CCathepsin LCathepsinsCell RespirationCellsCellular AssayCessation Of LifeChronicChronic InfectionAblationCrystallizationDesign
Grant awards (3)
Rational design of CNS-permeable cathepsin L inhibitors for treatment of chronic toxoplasmosis$423,128
R33 · FY2021 · AI
Rational design of CNS-permeable cathepsin L inhibitors for treatment of chronic toxoplasmosis$442,937
R33 · FY2020 · AI
Rational design of CNS-permeable cathepsin L inhibitors for treatment of chronic toxoplasmosis$459,688
R33 · FY2019 · AI